galunisertib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor. Development of galunisertib by Eli Lilly was discontinued in January 2020.   Wikipedia

Chemistry

  • SMILES: Cc1cccc(-c2nn3c(c2-c2ccnc4ccc(C(N)=O)cc24)CCC3)n1
  • InChIKey: IVRXNBXKWIJUQB-UHFFFAOYSA-N
  • Mol. Mass: 369.43
  • ALogP: 3.51
  • ChEMBL Molecule:
    galunisertib  
More Chemistry

Pharmacology

Alternative names

4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4h-pyrrolo(1,2-b)pyrazol-3-yl)quinoline-6-carboxylic acid amide | galunisertib | ly2157299 | ly 2157299 | ly-2157299

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Breast Neoplasms (Phase 1)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Glioma (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

Myelodysplastic Syndromes (Phase 2/Phase 3)

Nasopharyngeal Carcinoma (Phase 2)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms (Phase 1/Phase 2)

Ovarian Diseases (Phase 1)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 26
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue